Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference39 articles.
1. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma;Tobinai;Int J Clin Oncol.,2003
2. Alemtuzumab in CLL and other lymphoid neoplasms;Ravandi;Cancer Invest.,2006
3. Mechanism of action and resistance to monoclonal antibody therapy;Villamor;Semin Oncol.,2003
4. Novel therapeutic agents for B-cell lymphoma: developing rational combinations;Reeder;Blood.,2011
5. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor;Aqeilan;Biochem J.,2003
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Soluble CD40 ligand inhibits the growth of non‑Hodgkin's lymphoma cells through the JNK signaling pathway;Oncology Letters;2020-11-18
2. The potentials of immune checkpoints for the treatment of blood malignancies;Critical Reviews in Oncology/Hematology;2020-09
3. Selection and expression of CD40 single chain variable fragment by phage display and evaluation of tumor specific immune activation;International Immunopharmacology;2019-06
4. Induction of Apoptosis in Cancer Cells of pre-B ALL Patients after Exposure to Platelets, Platelet-Derived Microparticles and Soluble CD40 Ligand;CELL J;2018
5. Optimization and evaluation of Oridonin-loaded Soluplus ® -Pluronic P105 mixed micelles for oral administration;International Journal of Pharmaceutics;2017-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3